- Home
- DXCM vs ALC Comparison
DXCM vs ALC Comparison
Compare DXCM & ALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXCM | ALC |
|---|---|---|
| Founded | 1999 | 1945 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.1B | 32.4B |
| IPO Year | 2005 | 2002 |
Fundamental Metrics
Financial Performance| Metric | DXCM | ALC |
|---|---|---|
| Price | $72.13 | $64.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 12 |
| Target Price | $85.33 | ★ $89.38 |
| AVG Volume (30 Days) | ★ 5.4M | 2.0M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.25% |
| EPS Growth | ★ 47.18 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.46 | $7.99 |
| Revenue Next Year | $12.31 | $6.38 |
| P/E Ratio | $139.57 | ★ $38.31 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.11 | $61.84 |
| 52 Week High | $89.07 | $92.55 |
Technical Indicators
Market Signals| Indicator | DXCM | ALC |
|---|---|---|
| Relative Strength Index (RSI) | 52.70 | 41.32 |
| Support Level | $62.86 | $64.01 |
| Resistance Level | $74.08 | $81.92 |
| Average True Range (ATR) | 2.81 | 1.19 |
| MACD | -0.65 | 0.12 |
| Stochastic Oscillator | 15.11 | 21.62 |
Price Performance
Historical ComparisonAbout DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
About ALC Alcon Inc.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.